A positive control for our initial analyses was SBI-756, a small molecule eIF4F inhibitor that primarily targets eIF4G1 and is reportedly effective against several cancers (Feng et al., 2015; Herzog et al., 2021). This evidence concerns the gene EIF4E and cancer.